Departed
Adam R. Levy
Director
NXGL ·
NEXGEL, INC.
Mr. Levy resigned from the Company’s Board of Directors
Ready 8-Ks
50
Latest filing
August 21, 2026, 4:42 PM ET
Top materiality
1.00
Event mix
other_material ×18 · earnings ×12 · leadership ×11
Sentiment
18 pos · 4 neg · 28 neu
Latest earnings
reported 2026-Q2
Executive change
recent →
Recent 8-K filings for NXGL
Highest-materiality recent filing
NexGel closes Celularity regenerative biomaterials acquisition; expects revenue to triple to ~$35M
- Acquired Celularity's regenerative biomaterials portfolio for $13.3M ($8.3M cash + $5M convertible note); closed April 17, 2026.
- Raised $6.9M via convertible notes (10% interest, 18-month, $0.60 conversion) and warrants (5-year, $0.80 strike) to fund the deal.
-
NexGel terminates CEO Adam Levy, appoints Brian Kieser interim CEO, launches strategic review
Adam R. Levy terminated as CEO without cause effective Aug 21, 2026; resigned from board and all officer positions.
-
NexGel Q2 2026: revenue $3.69M, net loss $2.87M; BioNX backlog $795K; proxy vote fails
Q2 revenue $3.69M, net loss $2.87M; includes $756,554 BioNX amortization, $273,710 transaction costs, $144,495 SilverSeal recall.
-
NexGel annual meeting: reincorporation, share increase, reverse split all fail
All seven director nominees elected; Scott R. Henry resigned effective July 1, 2026.
-
CEO Adam Levy receives base salary of $375,000 per year under new employment agreement effective July 23, 2026.
-
NexGel postpones 2026 Annual Meeting to July 31 for proxy solicitation
Annual Meeting postponed from July 10 to July 31, 2026 at 10:00 a.m. ET.
-
NexGel director Scott Henry resigns effective July 1, 2026
Scott Henry notified NexGel of his resignation from the Board, effective July 1, 2026.
-
NexGel releases updated investor presentation for June 2026
Company began using a new investor presentation dated June 2026.
-
NexGel closes $1.21M private placement of convertible notes and warrants
Issued $1.21M aggregate principal amount of unsecured convertible notes at $0.60/share initial conversion price.
-
NEXGEL appoints two Sequence LifeScience leaders to board; Sequence led $5.5M financing
Brian J. Kieser (CEO) and Kevin M. Harris (COO) of Sequence LifeScience appointed to NEXGEL board effective May 6, 2026.
-
NexGel appoints Ian Blackman as CFO; Adam Drapczuk resigns as interim CFO
Ian Blackman appointed CFO effective April 27, 2026; CPA with over 30 years of finance leadership experience.
-
NexGel receives Nasdaq deficiency notice for bid price below $1; 180 days to cure
Closing bid price of common stock (NXGL) below $1.00 for 30 consecutive business days.
-
NexGel closes Celularity regenerative biomaterials acquisition; expects revenue to triple to ~$35M
Acquired Celularity's regenerative biomaterials portfolio for $13.3M ($8.3M cash + $5M convertible note); closed April 17, 2026.
-
NEXGEL signs $35M deal to buy Celularity's biomaterial portfolio; expects revenue to triple to ~$35M
Consideration up to $35M: $15M upfront plus $20M in milestone payments tied to net sales.
-
NexGel closes $1.8M Series A convertible note; up to $14.9M more for Q1 acquisition
Initial Series A convertible note raised $1,797,381 gross proceeds, bearing 10% interest (18% on default), convertible at $1.244/share with floor $0.2488.
-
Director Nachum Stein resigns from NexGel board effective February 2, 2026
Nachum Stein notified NexGel on January 29, 2026 of his resignation as Board member, effective February 2, 2026.
-
NexGel appoints Adam Drapczuk as Interim CFO, replacing Joseph McGuire effective Jan 1, 2026
Adam Drapczuk appointed Interim CFO effective Jan 1, 2026; succeeds Joseph F. McGuire terminated Dec 31, 2025.
-
NexGel spins off drug delivery program into NexGelRx; shareholders get 19.99% equity stake
NEXGEL spins off select Rx drug delivery assets into new entity NexGelRx; retains 19.99% non-dilutive equity stake.
-
NexGel cancels special meeting; drops proposal to increase authorized shares from 25M to 1B
Board voted on Nov 21, 2025 to cancel the Special Meeting scheduled for Nov 26, 2025.
-
NEXGEL Q3 revenue flat at $2.93M; net loss narrows to $0.65M
Net revenue $2.93M, virtually unchanged from $2.94M in Q3 2024.
-
NEXGEL Q2 revenue doubles to $2.88M, guided to $13M and positive EBITDA for FY2025
Revenue $2.88M, +100.3% YoY; gross margin 43.6% vs 20.3% YoY.
-
NEXGEL appoints Shutterstock CAO Steve Ciardiello, CPA, to its Board
Appointment effective July 31, 2025; Ciardiello also joins Audit Committee.
-
NEXGEL raises ~$1M in registered direct offering and private placement; warrants at $4.25
Registered direct offering of 413,044 shares at $2.30/share; gross proceeds ~$950,000.
-
NexGel furnishes new investor presentation; no material changes disclosed in filing
Began using a new investor presentation on July 31, 2025; furnished as Exhibit 99.1.
-
NEXGEL expands partnership with STADA; gets $1M non-dilutive capital for N.A. launches
Expansion includes digestive enzyme formulas and scar/stretch mark solutions for North America.
-
NexGel stockholders approve 780K share increase to incentive plan, elect directors
Stockholders approved Fourth Amendment to 2019 Long-Term Incentive Plan, increasing authorized shares by 780,000 to 1,651,429 total.
-
NexGel adopts investor presentation, no material new disclosures
New investor presentation used starting June 4, 2025; attached as Exhibit 99.1.
-
NexGel Q1 revenue $2.81M (+121% YoY); gross margin expands to 42.4% from 12.6%
Revenue $2.81M, up 121% YoY from $1.27M; guided Q1 slightly above prior outlook.
-
NexGel adopts new investor presentation; no material disclosures
Company began utilizing a new investor presentation on March 25, 2025.
-
NexGel Q4 revenue up 181% to $3.04M, guides 2025 revenue of $13M, positive EBITDA
Q4 revenue $3.04M (up 181% YoY); FY 2024 revenue $8.69M (up 112% YoY).
-
NEXGEL prelim Q4 rev ~$3M, FY2024 ~$8.6M (+100% YoY); guides FY2025 >$13M, cash flow positive
Preliminary Q4 2024 revenue ~$3.0M; full year ~$8.6M, representing >100% YoY growth for third consecutive year.
-
CEO Levy gets $375K salary, 150K options; McGuire named CFO
Adam Levy's 2025 employment agreement: base salary $375K (up $50K), 26,116 shares grant, 150K stock options at $3.829.
-
NEXGEL Q3 revenue record $2.94M (+141% YoY); gross margin expands to 43.6%
Net loss widened to $754K vs $552K Q3 2023, but improved from $979K Q2 2024; adjusted EBITDA loss narrowed to $347K.
-
NEXGEL raises ~$2M in registered direct offering of stock and warrants at $2.75/share
Offering of 727,272 common shares and warrants to buy 363,636 shares at $4.25; gross proceeds ~$2M.
-
NexGel adopts new investor presentation (Oct 2024); content not disclosed
Filed under Item 7.01 Regulation FD; presentation attached as Exhibit 99.1.
-
NexGel preannounces record Q3 2024 revenue of $2.85M, +133% YoY, +98% QoQ
Expected revenue $2.85M, up 133% YoY and 98% sequentially, beating prior $2.20M guidance by ~30%.
-
NEXGEL reports record Q2 revenue of $1.44M, net loss widens to $979K
Record Q2 revenue $1.44M, up 23.4% YoY; gross margin improved to 28.5% from 15.0%.
-
Gross proceeds of ~$1.11M from sale of 444K shares at $2.50/share and warrants exercisable at $4.25.
-
NexGel begins using new investor presentation as of July 29, 2024
New investor presentation adopted on July 29, 2024; content not disclosed in the 8-K.
-
NexGel reports preliminary Q2 revenue of $1.4M (+20% YoY); guides Q3 $2.2M, Q4 $2.6M
Preliminary Q2 2024 revenue of $1.4M, up ~20% YoY and ~10% sequentially.
-
NexGel stockholders elect five directors, ratify auditor at 2024 annual meeting
All five director nominees elected: Glassman (1,537,898 For), Henry (1,517,779), Levy (1,537,898), Stein (1,380,100), Zeldis (1,489,435).
-
NexGel acquires Silly George beauty brand for $600k cash+stock plus earn-out
Purchase price: $400k cash, $200k in NXGL common stock, and a 4-year net profit earn-out.
-
NEXGEL Q1 revenue $1.27M (+104% YoY); net loss $905K vs $807K YoY
Revenue increased 104% to $1.27M, driven by contract manufacturing (+58%) and branded products (+178%).
-
NEXGEL reports FY2023 revenue $4.1M (+99.7% YoY); net loss narrows to $3.2M
Revenue $4.1M for FY2023, up 99.7% YoY; Q4 revenue $1.1M, up 110% YoY.
-
NEXGEL raises ~$975k in registered direct offering led by insiders
Offering consists of 462,090 shares and warrants to buy 231,040 shares at $4.00, priced at $2.11 per share.
-
NexGel begins using new January 2024 investor presentation; no specific details released
NexGel announced it began using a new investor presentation dated January 2024.
-
Board member Miranda J. Toledano resigns effective March 31, 2024
Miranda J. Toledano notified NexGel on January 9, 2024 of her resignation from the Board effective March 31, 2024.
-
NexGel entered a one-year employment agreement with CEO Adam Levy, effective Jan 1, 2024, with $325,000 base salary and $70,000 equity grant.
-
Director David Stefansky resigns from NexGel board effective Dec 31, 2023
David Stefansky notified the company on Dec 7, 2023 of his resignation from the Board, effective Dec 31, 2023.
-
Partnership with STADA Arzneimittel AG, a European consumer health leader, for distribution and commercialization.
-
NexGel acquires Kenkoderm psoriasis skincare line for $546,500 initial cash plus earn-out
Initial cash payment of $546,500; earn-out up to additional $546,500 based on 2024 performance.
Executive changes
Appointed
(interim)
Brian Kieser
Interim Chief Executive Officer
NXGL ·
NEXGEL, INC.
Effective as of the Separation Date, the Board appointed Brian Kieser to serve as Interim Chief Executive Officer of the Company.
Departed
Adam R. Levy
Chief Executive Officer
NXGL ·
NEXGEL, INC.
Effective August 21, 2026 (the “ Separation Date ”), NexGel, Inc. (the “ Company ”) terminated Adam R. Levy’s employment as Chief Executive Officer without Cause (as defined in Mr. Levy’s Executive Employment Agreement, dated July 23, 2026), and Mr. Levy resigned from the Company’s Board of Directors (the “ Board ”) and from all other officer, director, committee and fiduciary positions held by him with the Company and its subsidiaries.
Appointed
Kevin M. Harris
Director
NXGL ·
NEXGEL, INC.
On May 6, 2026, Brian J. Kieser and Kevin M. Harris (collectively, the “ Board Appointees ”) were appointed to the board of directors
Appointed
Brian J. Kieser
Director
NXGL ·
NEXGEL, INC.
On May 6, 2026, Brian J. Kieser and Kevin M. Harris (collectively, the “ Board Appointees ”) were appointed to the board of directors
Departed
Adam Drapczuk
Chief Financial Officer
NXGL ·
NEXGEL, INC.
Mr. Blackman succeeds Mr. Drapczuk as the Company’s principal financial officer and principal accounting officer.
Appointed
Ian Blackman
Chief Financial Officer
NXGL ·
NEXGEL, INC.
the Board of Directors of the Company (the “ Board ”) appointed Ian Blackman, age 58, as Chief Financial Officer of NexGel, Inc. (the “ Company ”), effective April 27, 2026.
Appointed
Joseph F. McGuire
Chief Financial Officer
NXGL ·
NEXGEL, INC.
Joseph F. McGuire Appointment as Chief Financial Officer
Departed
Miranda J. Toledano
Director; Chairperson of Audit Committee; member of Nominating and Corporate Governance Committee
NXGL ·
NEXGEL, INC.
On January 9, 2024, Miranda J. Toledano notified NexGel, Inc. (the “ Company ”) of her intent to resign as a member of the Company’s Board of Directors (the “ Board ”) effective as of March 31, 2024.
Departed
David Stefansky
Director
NXGL ·
NEXGEL, INC.
On December 7, 2023, David Stefansky notified NexGel, Inc. (the “ Company ”) of his intent to resign as a member of the Company’s Board of Directors (the “ Board ”) effective as of December 31, 2023 to pursue other business ventures.
Departed
Yaakov Spinrad
Director
NXGL ·
NEXGEL, INC.
On January 16, 2023, Yaakov Spinrad resigned as a member of the Board.
Appointed
Scott R. Henry
Director
NXGL ·
NEXGEL, INC.
On January 16, 2023, Scott R. Henry (the “ Board Appointees ”) was appointed to the board of directors (the “ Board ”) of NexGel, Inc.
Earnings & guidance
Materiality & sentiment trend
Max materiality 1.00 · Median 0.60 · Most common event other_material